Tucatinib, in combination with trastuzumab and capecitabine, has received the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approval to be administered to women, with previously treated advanced HER2-positive breast cancer, with or without brain metastases. The gene discussed is ERBB2; the disease is breast carcinoma.